1
Hauptmann Rudolf Dr, Himmler Adolf Dr, Maurer Fogy Ingrid Dr, Stratowa Christian Dr: Tnf-receptor, tnf-binding protein and dna coding therefor.. Boehringer Ingelheim Int, October 24, 1990: EP0393438-A2 (123 worldwide citation)

DNA sequences coding for a TNF-binding protein and for the TNF receptor of which this protein represents the soluble domain. The DNA sequences can be used for the preparation of recombinant DNA molecules for the preparation of TNF-binding protein and TNF receptor. Recombinant TNF-binding protein is ...


2
Banholzer Rolf Dr, Bauer Rudolf Dr, Reichl Richard Dr: Thienylcarboxylic acid ester of aminoalcohols, their quaternary products, their preparation and use of the compounds.. Boehringer Ingelheim Kg, Boehringer Ingelheim Int, March 27, 1991: EP0418716-A1 (95 worldwide citation)

The new compounds of formula (I) (where A, R1, Ra and R2 are defined in the description) can be manufactured by processes known per se and used as the active ingredients of drugs.


3
Adolf Guenther, Baum Anke, Heider Karl Heinz: Compositions and methods for treating cancer using maytansinoid cd44 antibody immunoconjugates and chemotherapeutic agents. Boehringer Ingelheim Int, February 25, 2004: EP1391213-A1 (67 worldwide citation)

The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates cont ...


4
Park John Edward, Garin Chesa Pilar, Bamberger Uwe, Leger Olivier, Saldanha Jose, Rettig Wolfgang J: Fapalpha-specific antibody with improved producibility. Boehringer Ingelheim Int, November 3, 1999: EP0953639-A1 (49 worldwide citation)

Recombinant antibody proteins are provided that specifically bind fibroblast activation protein alpha (FAP alpha ) and comprise framework modifications resulting in the improved producibility in host cells. The invention also relates to the use of said antibodies for diagnostic and therapeutic purpo ...


5
Walther Gerhard Dr, Kuefner Muehl Dr, Stransky Werner Dr, Weber Karl Heinz Dr, Ensinger Helmut Dr, Kuhn Franz Josef Dr, Mueller Enzio Prof Dr: Bicyclic 1-azacycloalcanes.. Boehringer Ingelheim Kg, Boehringer Ingelheim Int, November 27, 1991: EP0458214-A1 (36 worldwide citation)

The invention relates to bicyclic 1-azacycloalkanes, to processes for their preparation and to their use as medicaments having cholinomimetic properties.


6

7
Weber Karl Heinz Dr Dipl Chem, Harreus Albrecht Dr Dipl Chem, Stransky Werner Dr Dipl Chem, Walther Gerhard Dr Dipl Chem, Casals Stenzel Jorge Dr, Muacevic Gojko Dr, Heuer Hubert Dr, Bechtel Wolf Dietrich Dr: Hetrazepins and processes for their preparation.. Boehringer Ingelheim Kg, Boehringer Ingelheim Int, January 27, 1988: EP0254245-A1 (32 worldwide citation)

Hetrazepines of the formula in which A, Z, n, X, Y, R1, R2, R3 and R4 have the meaning mentioned in the description. The novel compounds are to be used for the treatment of pathological conditions and diseases in which PAF (platelet-activating factor) is involved.


8

9
Beug Hartmut Dr, Birnstiel Max L Prof Dr, Cotten Matthew Dr, Wagner Ernst Dr, Kandolf Harald Dipl Ing: Genetic construct for inhibiting rna function.. Boehringer Ingelheim Int, September 19, 1990: EP0387775-A1 (32 worldwide citation)

The invention relates to a genetic unit, which is optionally in multicopy form, for the inhibition of RNA. The unit contains the transcription units necessary for transcription by polymerase III, and a DNA which codes for inhibiting RNA and which is arranged within the unit in such a way that the tr ...


10
Heckl Konrad Dr, Spevak Walter Dr, Ostermann Elinborg Dr, Zophel Andreas Dr, Krystek Edeltraud Dr, Maurer Fogy Ingrid Dr, Wiche Castanon Maria Josefa Dr, Stratowa Christian Dr, Hauptmann Rudolf Dr: Human manganese superoxide dismutase (hmn-sod).. Boehringer Ingelheim Int, September 21, 1988: EP0282899-A2 (31 worldwide citation)

A genetic engineering method for the production of human Mn superoxide dismutase (hMn-SOD), the DNA sequences which code for this enzyme, suitable vectors which contains these DNA sequences and host cells which can express these DNA sequences, as well as the enzyme hMn-SOD itself are described. Prop ...